JP2014532402A5 - - Google Patents

Download PDF

Info

Publication number
JP2014532402A5
JP2014532402A5 JP2014537726A JP2014537726A JP2014532402A5 JP 2014532402 A5 JP2014532402 A5 JP 2014532402A5 JP 2014537726 A JP2014537726 A JP 2014537726A JP 2014537726 A JP2014537726 A JP 2014537726A JP 2014532402 A5 JP2014532402 A5 JP 2014532402A5
Authority
JP
Japan
Prior art keywords
construct
aadc
viral
item
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014537726A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014532402A (ja
JP6296987B2 (ja
Filing date
Publication date
Priority claimed from GBGB1118636.8A external-priority patent/GB201118636D0/en
Application filed filed Critical
Publication of JP2014532402A publication Critical patent/JP2014532402A/ja
Publication of JP2014532402A5 publication Critical patent/JP2014532402A5/ja
Application granted granted Critical
Publication of JP6296987B2 publication Critical patent/JP6296987B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014537726A 2011-10-28 2012-10-26 構築物 Active JP6296987B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161552581P 2011-10-28 2011-10-28
GBGB1118636.8A GB201118636D0 (en) 2011-10-28 2011-10-28 Nucleotide sequence
GB1118636.8 2011-10-28
US61/552,581 2011-10-28
PCT/GB2012/052668 WO2013061076A1 (en) 2011-10-28 2012-10-26 Construct

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018027852A Division JP6698114B2 (ja) 2011-10-28 2018-02-20 構築物

Publications (3)

Publication Number Publication Date
JP2014532402A JP2014532402A (ja) 2014-12-08
JP2014532402A5 true JP2014532402A5 (cg-RX-API-DMAC7.html) 2015-11-12
JP6296987B2 JP6296987B2 (ja) 2018-03-20

Family

ID=45373567

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014537726A Active JP6296987B2 (ja) 2011-10-28 2012-10-26 構築物

Country Status (11)

Country Link
US (1) US11279954B2 (cg-RX-API-DMAC7.html)
EP (2) EP2771471B1 (cg-RX-API-DMAC7.html)
JP (1) JP6296987B2 (cg-RX-API-DMAC7.html)
CN (2) CN104011213B (cg-RX-API-DMAC7.html)
AU (1) AU2012328166B2 (cg-RX-API-DMAC7.html)
CA (2) CA2849241C (cg-RX-API-DMAC7.html)
DK (2) DK3219801T3 (cg-RX-API-DMAC7.html)
ES (2) ES2628419T3 (cg-RX-API-DMAC7.html)
GB (1) GB201118636D0 (cg-RX-API-DMAC7.html)
PL (2) PL2771471T3 (cg-RX-API-DMAC7.html)
WO (1) WO2013061076A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
RU2020109343A (ru) 2014-11-05 2020-03-17 Вояджер Терапьютикс, Инк. Полинуклеотиды aadc для лечения болезни паркинсона
EP3331570A1 (en) * 2015-08-03 2018-06-13 Myodopa Limited Systemic synthesis and regulation of l-dopa
GB2562774A (en) * 2017-05-25 2018-11-28 Mcdonald Michael Genetic construct
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3099306A1 (en) 2018-05-15 2019-11-21 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
CN116024271A (zh) * 2018-05-31 2023-04-28 康霖生物科技(杭州)有限公司 一种用于中枢神经系统疾病治疗的基因序列构建体
EP3856762A1 (en) 2018-09-28 2021-08-04 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
US20220175962A1 (en) * 2019-03-10 2022-06-09 Sio Gene Therapies Inc. Gene therapy compositions and methods for treating parkinson's disease
CN109971729B (zh) * 2019-04-19 2021-07-16 上海信致医药科技有限公司 一种酶组合物
GB2587319A (en) 2019-08-12 2021-03-31 Healing Genes Llc Genetic construct
CN113388642B (zh) * 2020-03-13 2023-05-30 康霖生物科技(杭州)有限公司 一种核酸构建体
GB2601752A (en) 2020-12-08 2022-06-15 Maavrx Ltd Expression vector
EP4448774A1 (en) 2021-12-17 2024-10-23 Imperial College Innovations Limited Rna construct
CN114317610B (zh) * 2022-01-27 2024-07-02 上海本导基因技术有限公司 一种适用于帕金森疾病基因治疗的慢病毒载体
CN117106825B (zh) * 2023-08-28 2024-11-01 康霖生物科技(杭州)有限公司 用于治疗帕金森病的基因治疗载体及其用途
CN118389675B (zh) * 2024-05-27 2025-06-27 南方医科大学珠江医院 芳香族氨基酸脱羧酶作为标志物在肝性脑病的检测产品中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
DE4006630A1 (de) 1990-03-03 1991-09-12 Behringwerke Ag Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
US5512421A (en) 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
EP0593614B1 (en) 1991-06-21 1997-10-15 Phillips Petroleum Company Method for increasing rainout from autorefrigerated vaporous cloud containing hydrofluoric acid
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
AU1073797A (en) * 1995-11-14 1997-06-05 Somatix Therapy Corporation Joint expression of gtp cyclohydrolase and tyrosine hydroxylase
US5866552A (en) 1996-09-06 1999-02-02 The Trustees Of The University Of Pennsylvania Method for expressing a gene in the absence of an immune response
AU725143B2 (en) 1996-10-17 2000-10-05 Oxford Biomedica (Uk) Limited Retroviral vectors
GB9622500D0 (en) * 1996-10-29 1997-01-08 Oxford Biomedica Ltd Therapeutic gene
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
AU763007B2 (en) 1998-05-22 2003-07-10 Oxford Biomedica (Uk) Limited Retroviral delivery system
GB9904905D0 (en) 1999-03-03 1999-04-28 Oxford Biomedica Ltd Cells
US6857241B1 (en) 1999-07-13 2005-02-22 Carlos Fradera Pellicer Building panel and plant for the manufacture thereof
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
GB0024550D0 (cg-RX-API-DMAC7.html) * 2000-10-06 2000-11-22 Oxford Biomedica Ltd
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
DK2348119T3 (en) 2002-02-01 2017-08-21 Oxford Biomedica (Uk) Ltd Polycistronic lentiviral vector
SE0302509D0 (sv) 2003-09-19 2003-09-19 Amersham Biosciences Ab Matrix for separation of polyethers and method of separation
US7943374B2 (en) 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
GB0526210D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Vectors
GB0526211D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Viral vectors
US20090214478A1 (en) 2008-02-21 2009-08-27 Alberto Auricchio Method of treating ocular diseases by gene therapy
JP5615271B2 (ja) 2008-06-18 2014-10-29 オックスフォード バイオメディカ(ユーケー)リミテッド ウイルス精製法
US20110269826A1 (en) * 2008-11-11 2011-11-03 Oxford Biomedica (Uk) Limited Method
ES2536791T3 (es) * 2010-05-28 2015-05-28 Oxford Biomedica (Uk) Ltd Administración de vectores lentivirales al cerebro

Similar Documents

Publication Publication Date Title
JP2014532402A5 (cg-RX-API-DMAC7.html)
JP2022031942A (ja) 広域インフルエンザウイルスワクチン
JP5432415B2 (ja) キャッピングプローンrnaポリメラーゼ酵素およびその適用
JP2021508234A (ja) ACE−tRNAを用いた遺伝的再帰属を介して終止コドンレスキューする方法
JP2016538830A5 (cg-RX-API-DMAC7.html)
Emonet et al. Arenavirus reverse genetics: new approaches for the investigation of arenavirus biology and development of antiviral strategies
WO2017011773A3 (en) Codon-optimized nucleic acids encoding antibodies
JP2017532966A5 (cg-RX-API-DMAC7.html)
JP2015513897A5 (cg-RX-API-DMAC7.html)
Muto et al. Peptidyl-prolyl-tRNA at the ribosomal P-site reacts poorly with puromycin
JP2017070289A5 (cg-RX-API-DMAC7.html)
EP4582098A3 (en) Optimized nucleic acid molecules
JP2019517790A5 (cg-RX-API-DMAC7.html)
WO2010105251A3 (en) Non-integrating retroviral vector vaccines
JP2017538401A5 (cg-RX-API-DMAC7.html)
WO2013151670A3 (en) Modified polynucleotides for the production of nuclear proteins
MX2019015502A (es) L-asparaginasa modificada.
WO2011147590A3 (en) Tailored recombinase for recombining asymmetric target sites in a plurality of retrovirus strains
JP2019519529A5 (cg-RX-API-DMAC7.html)
JP2017524380A5 (ja) 腫瘍血管遮断剤であるポリペプチド、遺伝子、発現ベクター、腫瘍血管遮断剤の組成物、及び腫瘍血管遮断剤であるポリペプチドの調製方法
JP2012529293A5 (cg-RX-API-DMAC7.html)
EP2527445A3 (en) Treatment and prevention of influenza
MY173686A (en) Fc gamma receptor iib variants
JP2016520534A5 (cg-RX-API-DMAC7.html)
WO2008049643A3 (en) Gd2 peptide mimotopes for anticancer vaccination